Blueprint Medicines
Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.
Founded
2008Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.
Blueprint Medicines, founded in Cambridge, US, is dedicated to developing targeted cancer treatments for genomically defined patients. The company's core mission is to improve patient outcomes by creating precision therapies that address the molecular underpinnings of cancer. Blueprint Medicines offers a range of products, including AYVAKIT®/AYVAKYT® (avapritinib), which targets specific genetic mutations in cancer cells. Their market focus is on providing innovative solutions for patients with rare and difficult-to-treat cancers.
Notable affiliated individuals include industry experts and seasoned professionals in biomedical research and oncology. The company has attracted significant investment from leading healthcare investors. Key achievements include presenting promising clinical data at major conferences such as EAACI, EHA, and ASCO, highlighting the sustained benefits of their therapies. Blueprint Medicines has made a substantial impact on the field of precision oncology, offering hope and improved treatment options for patients with genetically defined cancers.
Companies similar to Blueprint Medicines include Deciphera Pharmaceuticals, Revolution Medicines, Clovis Oncology and Accelerated Pharma.
Blueprint Medicines was founded in 2008.
Blueprint Medicines' headquarters is located in Cambridge, MA, US.
Blueprint Medicines' most recent funding round was for $1.3B (USD) in June 2022.
As of Jun 30, 2022, Blueprint Medicines has disclosed funding of $2.4B (USD). Undisclosed round amounts are excluded.
Blueprint Medicines has 641 employees as of Feb 6, 2024.
Accelerated Pharma
